Analysts expect Dova Pharmaceuticals Inc (NASDAQ:DOVA) to report ($0.60) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Dova Pharmaceuticals’ earnings, with estimates ranging from ($0.67) to ($0.51). Dova Pharmaceuticals posted earnings per share of ($0.70) in the same quarter last year, which indicates a positive year-over-year growth rate of 14.3%. The company is scheduled to report its next quarterly earnings report on Thursday, August 8th.
According to Zacks, analysts expect that Dova Pharmaceuticals will report full year earnings of ($2.10) per share for the current financial year, with EPS estimates ranging from ($2.34) to ($1.81). For the next fiscal year, analysts forecast that the business will post earnings of ($0.72) per share, with EPS estimates ranging from ($1.84) to $0.15. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its earnings results on Tuesday, May 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.10. The company had revenue of $4.00 million for the quarter, compared to analyst estimates of $3.46 million. Dova Pharmaceuticals had a negative net margin of 521.67% and a negative return on equity of 87.20%.
A number of research firms have issued reports on DOVA. BidaskClub upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Dova Pharmaceuticals in a report on Friday, April 26th. Finally, JPMorgan Chase & Co. lowered shares of Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and reduced their target price for the stock from $34.00 to $20.00 in a report on Wednesday, January 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. Dova Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $29.57.
In other news, Director Paul B. Manning acquired 68,000 shares of Dova Pharmaceuticals stock in a transaction dated Thursday, March 7th. The shares were acquired at an average cost of $7.48 per share, for a total transaction of $508,640.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 60.30% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Dova Pharmaceuticals by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 619,604 shares of the company’s stock worth $12,993,000 after acquiring an additional 14,985 shares in the last quarter. Broadfin Capital LLC acquired a new stake in Dova Pharmaceuticals during the 4th quarter worth $2,667,000. BlackRock Inc. raised its stake in Dova Pharmaceuticals by 0.8% during the 3rd quarter. BlackRock Inc. now owns 1,154,232 shares of the company’s stock worth $24,204,000 after acquiring an additional 9,312 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Dova Pharmaceuticals by 14,705.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock worth $38,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in Dova Pharmaceuticals by 19.8% during the 3rd quarter. Teachers Advisors LLC now owns 21,561 shares of the company’s stock worth $452,000 after acquiring an additional 3,556 shares in the last quarter. Institutional investors and hedge funds own 31.17% of the company’s stock.
Dova Pharmaceuticals stock traded down $0.85 during mid-day trading on Friday, reaching $10.68. 11,050 shares of the company’s stock were exchanged, compared to its average volume of 165,356. The firm has a market cap of $315.36 million, a PE ratio of -4.17 and a beta of 2.06. Dova Pharmaceuticals has a twelve month low of $5.62 and a twelve month high of $35.33. The company has a quick ratio of 4.27, a current ratio of 4.46 and a debt-to-equity ratio of 0.20.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
See Also: What is a Lock-Up Period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.